Margherita Grattarola
Turin, 10125, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Establishment of a mouse hepatocellular carcinoma tumoroid panel recapitulating inter- and intra- heterogeneity for disease modelling and combinatorial drug discovery.
Journal: Cell communication and signaling : CCS
Published: June 03, 2025
The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically active.
Journal: Nature communications
Published: July 13, 2023
Nrf2 as a Therapeutic Target in the Resistance to Targeted Therapies in Melanoma.
Journal: Antioxidants (Basel, Switzerland)
Published: May 25, 2023
Surface Functionalised Parenteral Nanoemulsions for Active and Homotypic Targeting to Melanoma.
Journal: Pharmaceutics
Published: February 24, 2023
Exploiting Nanomedicine for Cancer Polychemotherapy: Recent Advances and Clinical Applications.
Journal: Pharmaceutics
Published: January 20, 2023
Microbiota, Oxidative Stress, and Skin Cancer: An Unexpected Triangle.
Journal: Antioxidants (Basel, Switzerland)
Published: December 29, 2022
Oxidative Stress-Related Mechanisms in Melanoma and in the Acquired Resistance to Targeted Therapies.
Journal: Antioxidants (Basel, Switzerland)
Published: October 31, 2021
Post-translational down-regulation of Nrf2 and YAP proteins, by targeting deubiquitinases, reduces growth and chemoresistance in pancreatic cancer cells.
Journal: Free radical biology & medicine
Published: June 17, 2021
Control of Oxidative Stress in Cancer Chemoresistance: Spotlight on Nrf2 Role.
Journal: Antioxidants (Basel, Switzerland)
Published: February 25, 2021
Carbosilane Dendrimers Loaded with siRNA Targeting Nrf2 as a Tool to Overcome Cisplatin Chemoresistance in Bladder Cancer Cells.
Journal: Antioxidants (Basel, Switzerland)
Published: September 25, 2020
Last Updated: 09/26/2026